logo-loader
RNS
viewAstraZeneca

Block listing Interim Review

/**/ em{letter-spacing:.5pt;border:none windowtext 1.0pt;padding:0cm;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .an{size:21.0cm 842.0pt;margin:3.0cm 72.0pt 0cm 72.0pt;}div.an{}p.cj{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;line-height:normal}span.ch{font-weight:normal}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: center}span.cf{font-size:12.0pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";}span.cd{font-variant:small-caps}table.cl{width:451.35pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.cb{width:49.86%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.cm{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm}td.ca{width:50.14%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.bz{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.by{width:50.14%;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bx{width:37.18%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.bw{width:12.68%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bv{width:19.0%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bu{width:8.44%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bt{width:22.7%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bs{border:none} td.bq{width:49.84%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bp{width:50.16%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.bo{width:49.84%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.bn{width:50.16%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold}p.co{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify}span.bk{color:black}span.bj{color: blue; text-decoration: underline}table.cq{width:435.25pt;margin-left:-5.4pt;border-collapse:collapse} tr.bb{height:21.15pt}td.be{width:34.38%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;}span.bh{font-size:10.0pt}p.cs{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; page-break-after: avoid; text-align: justify; text-indent: -5.5pt}td.bd{width:43.76%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}td.bc{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}tr.aw{height:19.85pt}td.az{width:34.38%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt} td.ay{width:43.76%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.ax{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.av{width:34.38%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.au{width:43.76%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.at{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}span.as{font-size:10.0pt;color:black}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt;page-break-after: avoid}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-autospace:none;vertical-align: middle}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}span.ao{font-size: 10.0pt;font-family:"Arial","sans-serif"} /**/
RNS Number : 8391A
AstraZeneca PLC
03 June 2019
 

3 June 2019 15:00 BST

 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 3 June 2019

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

1 December 2018

To:

31 May 2019

Balance of unallotted securities under scheme(s) from previous return:

1,827,017

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

578,981

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,248,036

 

Name of contact:

CAMILLA WISEMAN

Telephone number of contact:

020 3749 5000

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

 

Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharma

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma (cardiovascular; metabolism)

+44 203 749 5711

Nick Stone

BioPharma (respiratory; renal)

+44 203 749 5716

Josie Afolabi

Other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRSDUFWFFUSELI

Quick facts: AstraZeneca

Price: 7383

Market: LSE
Market Cap: £96.86 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE